Relation Between Plaque Progression and Low-Density Lipoprotein Cholesterol During Aging as Assessed With Serial Long-Term (≥12 Months) Follow-Up Intravascular Ultrasound of the Left Main Coronary Artery

American Journal of Cardiology

Volumn 98, Issue 11, 2006, Pages 1419-1423

  Hartmann, Marc ^a   von Birgelen, Clemens ^a   Mintz, Gary S ^b   van Houwelingen, Gert K ^a   Eggebrecht, Holger ^c   Böse, Dirk ^c   Wieneke, Heinrich ^c   Verhorst, Patrick M J ^a   Erbel, Raimund ^c  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC ACID DERIVATIVE; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; AGING; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DISEASE COURSE; FOLLOW UP; HUMAN; INTRAVASCULAR ULTRASOUND; LEFT CORONARY ARTERY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; AGING; CHOLESTEROL, LDL; CORONARY VESSELS; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 33751187537     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.06.042     Document Type: Article

References (28)

1. Curb J.D., Abbott R.D., Rodriguez B.L., Masaki K., Popper J., Chen R., Petrovitch H., Blanchette P., Schatz I., and Yano K. Prospective association between low and high total lipoprotein cholesterol and coronary heart disease in elderly men. J Am Geriatr Soc 52 (2004) 1975-1980
2. Lloyd-Jones D.M., Wilson P.W.F., Larson M.G., Leip E., Beiser A., D'Agostino R.B., Cleeman J.I., and Levy D. Lifetime risk of coronary heart disease by cholesterol levels at selected ages. Arch Intern Med 163 (2003) 1966-1972
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
4. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. PROspective Study of Pravastatin in the Elderly at Risk. Lancet 360 (2002) 1623-1630
5. Hunt D., Young P., Simes J., Hague W., Mann S., Owensby D., Lane G., and Tonkin A. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 134 (2001) 931-940
6. Collins R., and Armitage J. High-risk elderly patients PROSPER from cholesterol-lowering therapy. Lancet 360 (2002) 1618-1619
7. Grundy S.M., Cleeman J.I., Merz C.N.B., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., Stone N.J., and Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44 (2004) 720-732
8. Williams M.A., Fleg J.L., Ades P.A., Chaitman B.R., Miller N.H., Mohiuddin S.M., Ockene I.S., Taylor C.B., and Wenger N.K. Secondary Prevention of Coronary Heart Disease in the Elderly (With Emphasis on Patients >75 Years of Age): an American Heart Association Scientific Statement From the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 105 (2002) 1735-1743
9. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., and Gotto A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS Airforce/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
10. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J., and West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
11. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., et al., Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
12. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
13. von Birgelen C., Hartmann M., Mintz G.S., Baumgart D., Schmermund A., and Erbel R. Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (≥12 months) follow-up intravascular ultrasound. Circulation 108 (2003) 2757-2762
14. von Birgelen C., Hartmann M., Mintz G.S., van Houwelingen K.G., Deppermann N., Schmermund A., Bose D., Eggebrecht H., Neumann T., Gossl M., et al. Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. Circulation 110 (2004) 1579-1585
15. von Birgelen C., Hartmann M., Mintz G.S., Böse D., Eggebrecht H., Neumann T., Mario G., Wieneke H., Schmermund A., Stoel M.G., et al. Remodeling index compared to actual vascular remodeling in atherosclerotic left main coronary arteries as assessed with long-term (≥12 months) serial intravascular ultrasound. J Am Coll Cardiol 47 (2006) 1363-1368
16. Mintz G.S., Nissen S.E., Anderson W.D., Bailey S.R., Erbel R., Fitzgerald P.J., Pinto F.J., Rosenfield K., Siegel R.J., Tuzcu E.M., and Yock P.G. American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS). J Am Coll Cardiol 37 (2001) 1478-1492
17. Baumgart D., Haude, Ge J., Gorge G., Liu F., Shah V., and Erbel R. Online integration of intravascular ultrasound images into angiographic images. Cathet Cardiovasc Diagn 39 (1996) 328-329
18. Devereux R.B., and Alderman M.H. Role of preclinical cardiovascular disease in evolution from risk factor exposure to development of morbid events. Circulation 88 (1993) 1444-1455
19. Waters D., Craven T.E., and Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 87 (1993) 1399-1401
20. Maron D.J., Fazio S., and Linton M.F. Current perspectives on statins. Circulation 101 (2000) 207-213
21. Taylor A., Shaw L.J., Fayad Z., O'Leary D., Browne B.G., Nissen S., Rader D., and Raggi P. Tracking atherosclerosis regression: a clinical tool in preventive cardiology. Atherosclerosis 180 (2005) 1-10
22. Nissen S.E., Tuzcu E.M., Schoenhagen P., Brown B.G., Ganz P., Vogel R.A., Crowe T., Howard G., Cooper C.J., Brodie B., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA 291 (2004) 1071-1080
23. Jensen L.O., Thayssen P., Pederson K.E., Stender S., and Haghfelt T. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation 110 (2004) 265-270
24. Schartl M., Bocksch W., Koschyk D.H., Voelker W., Karsch K.R., Kreuzer J., Hausmann D., Beckmann S., and Gross M. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 104 (2001) 387-392
25. Larosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., and Wenger N.K. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
26. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., and Skene A.M. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
27. Kawasaki M., Sano K., Okubo M., Yokoyama H., Ito Y., Murata I., Tsuchiya K., Minatoguchi S., Zhou X., Fujita H., and Fujiwara H. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol 45 (2005) 1946-1953
28. von Birgelen C., de Vrey E.A., Mintz G.S., Nicosia A., Bruining N., Li W., Slager C.J., Roelandt J.R., Serruys P.W., and de Feyter P.J. ECG-gated three-dimensional intravascular ultrasound: feasibility and reproducibility of the automated analysis of coronary lumen and atherosclerotic plaque dimensions in humans. Circulation 96 (1997) 2944-2952